Vincerx Pharma Files 8-K on Jan 12 Event; Confirms Nasdaq Listing

TL;DR

**Vincerx Pharma filed a routine 8-K, mostly administrative, no major news.**

AI Summary

Vincerx Pharma, Inc. filed an 8-K on January 16, 2024, reporting an 'Other Event' that occurred on January 12, 2024. This filing primarily updates administrative information, confirming its status as a Delaware corporation with its principal office at 260 Sheridan Avenue, Suite 400, Palo Alto, California, and its common stock (VINC) listed on The Nasdaq Stock Market LLC. For investors, this filing is largely administrative and does not contain new financial or operational news that would directly impact the stock's value, but it confirms the company's current public listing details.

Why It Matters

This filing is largely administrative, confirming Vincerx Pharma's corporate details and Nasdaq listing, which is important for maintaining transparency and regulatory compliance but offers no new material financial insights.

Risk Assessment

Risk Level: low — This filing is purely administrative and does not introduce any new financial or operational risks to the company.

Analyst Insight

A smart investor would note this filing as a routine administrative update, confirming basic company information. It does not contain new material information that would warrant immediate trading action, but it's a good reminder to ensure all company details are current.

Key Numbers

• 001-39244 — Commission File Number (Vincerx Pharma's SEC file number)
• 83-3197402 — I.R.S. Employer Identification No. (Vincerx Pharma's IRS EIN)
• $0.0001 — par value per share (par value of Vincerx Pharma's Common Stock)

Key Players & Entities

• Vincerx Pharma, Inc. (company) — registrant filing the 8-K
• Delaware (company) — state of incorporation for Vincerx Pharma, Inc.
• The Nasdaq Stock Market LLC (company) — exchange where Vincerx Pharma's common stock is registered
• VINC (company) — trading symbol for Vincerx Pharma's common stock
• January 12, 2024 (date) — date of the earliest event reported in the 8-K
• January 16, 2024 (date) — date the 8-K was filed
• 260 Sheridan Avenue, Suite 400, Palo Alto, California (company) — address of principal executive offices for Vincerx Pharma, Inc.
• 650-800-6676 (dollar_amount) — registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share VINC The Nasdaq
• $1.00 — Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company

Filing Documents

• d699758d8k.htm (8-K) — 21KB
• 0001193125-24-008013.txt ( ) — 143KB
• vinc-20240112.xsd (EX-101.SCH) — 3KB
• vinc-20240112_lab.xml (EX-101.LAB) — 18KB
• vinc-20240112_pre.xml (EX-101.PRE) — 11KB
• d699758d8k_htm.xml (XML) — 3KB

01

Item 8.01 Other Events. On January 12, 2024, Vincerx Pharma, Inc. (the "Company") received written notice (the "Compliance Notice") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Capital Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from December 28, 2023 to January 11, 2024, the closing bid price of the Company's common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 16, 2024 VINCERX PHARMA, INC. By: /s/ Raquel E. Izumi Name: Raquel E. Izumi Title: President and Chief Operations Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR